Article
Health Care Sciences & Services
Pune N. Paque, Christopher Herz, Daniel B. Wiedemeier, Konstantinos Mitsakakis, Thomas Attin, Kai Bao, Georgios N. Belibasakis, John P. Hays, Joel S. Jenzer, Wendy E. Kaman, Michal Karpisek, Philipp Korner, Johannes R. Peham, Patrick R. Schmidlin, Thomas Thurnheer, Florian J. Wegehaupt, Nagihan Bostanci
Summary: This study identified four salivary biomarkers crucial for predicting caries accurately and developed an RF model for classification and prediction of caries progression. The high correlation between RF prediction and clinical classification was observed, indicating a new approach for caries identification.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Miao Su, Zhe Zhang, Li Zhou, Chao Han, Canhua Huang, Edouard C. Nice
Summary: Cancer is a major global public health issue and personalized/precision medicine plays a crucial role in its diagnosis and treatment. Research focuses on cancer biomarkers, the impact of the microbiome, the application of emerging omics technologies, and future prospects.
Review
Oncology
Cynthia Aristei, Elisabetta Perrucci, Emanuele Ali, Fabio Marazzi, Valeria Masiello, Simonetta Saldi, Gianluca Ingrosso
Summary: Breast cancer, as the most common malignancy in women, requires personalized treatment approaches in radiation oncology. While systemic therapies based on molecular subtypes are personalized, personalized radiation therapy is still in development to better tailor treatment and improve outcomes. Efforts are being made to identify prognostic factors and biomarkers for personalized radiation therapy selection.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Kamya Sankar, Jing Christine Ye, Zihai Li, Lei Zheng, Wenru Song, Siwen Hu-Lieskovan
Summary: Immune checkpoint inhibitors have greatly improved the survival of cancer patients, but the wide variability in clinical response remains a significant limitation. This review explores the biomarkers that have been approved or are under investigation, focusing on their predictive role in patient response to immunotherapy. The authors also discuss the potential of combination biomarker strategies and the need for standardization in clinical trial design to advance precision immuno-oncology.
BIOMARKER RESEARCH
(2022)
Article
Health Care Sciences & Services
Michael Kenn, Rudolf Karch, Dan Cacsire Castillo-Tong, Christian F. Singer, Heinz Koelbl, Wolfgang Schreiner
Summary: The presence or absence of estrogen and progesterone receptors is an important biomarker for therapy selection in breast cancer patients. Conventional immunohistochemistry measurement has errors, and there have been attempts to increase precision by incorporating gene expression information. Dempster-Shafer decision theory (DST) is a suitable approach for dealing with contradicting evidence obtained through different techniques. This study compares DST with classical statistics in the context of breast cancer patient data, aiming to demonstrate the potential applications of DST in medicine.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Oncology
Muhammad Javed Iqbal, Zeeshan Javed, Jesus Herrera-Bravo, Haleema Sadia, Faiza Anum, Shahid Raza, Arifa Tahir, Muhammad Naeem Shahwani, Javad Sharifi-Rad, Daniela Calina, William C. Cho
Summary: Recent technological advances in nanoscience and material design have led to the development of point-of-care devices for biomolecule sensing and cancer diagnosis, with improved sensitivity and specificity. These innovations show great promise for clinical breakthroughs in cancer detection and diagnosis.
CANCER CELL INTERNATIONAL
(2022)
Review
Chemistry, Analytical
Josephine Aidoo-Brown, Despina Moschou, Pedro Estrela
Summary: This review discusses recent research on using optical and electrochemical biosensor platforms for multiplexed detection of PCa protein biomarkers, aiming to improve the diagnostic, surveillance, and treatment management of prostate cancer patients, and the importance of converting research protocols into multiplex point-of-care testing devices for use in near-patient settings.
Review
Oncology
Simona-Ruxandra Volovat, Iolanda Augustin, Daniela Zob, Diana Boboc, Florin Amurariti, Constantin Volovat, Cipriana Stefanescu, Cati Raluca Stolniceanu, Manuela Ciocoiu, Eduard Alexandru Dumitras, Mihai Danciu, Delia Gabriela Ciobanu Apostol, Vasile Drug, Sinziana Al Shurbaji, Lucia-Georgiana Coca, Florin Leon, Adrian Iftene, Paul-Corneliu Herghelegiu
Summary: This article provides an overview of the molecular classification of colorectal cancer and its relationship with epigenetic alterations. It also discusses the identification of prognostic and predictive biomarkers in metastatic colorectal cancer. The composition of the intestinal microbiota is found to be an important biomarker for the response to immune-based therapy in colorectal cancer. Additionally, the use of artificial intelligence technology can enhance the identification of biomarkers.
Article
Oncology
Maxim Sorokin, Marianna Zolotovskaia, Daniil Nikitin, Maria Suntsova, Elena Poddubskaya, Alexander Glusker, Andrew Garazha, Alexey Moisseev, Xinmin Li, Marina Sekacheva, David Naskhletashvili, Alexander Seryakov, Ye Wang, Anton Buzdin
Summary: RNA sequencing analysis of tumor FFPE materials may be helpful for personalizing prescriptions of targeted therapeutics in CRC. The Oncobox drug efficiency score is an effective biomarker that can predict treatment outcomes, especially for bevacizumab.
Article
Multidisciplinary Sciences
Fabi Prezja, Sami Ayramo, Ilkka Polonen, Timo Ojala, Suvi Lahtinen, Pekka Ruusuvuori, Teijo Kuopio
Summary: This study utilized stained biopsy slides to extract CNN-based biomarkers for predicting clinical outcomes in colorectal cancer patients. By refining the training strategy of an established CNN model, the researchers achieved higher accuracy and reduced errors in relevant biomarker classes. This study also introduced interpretability methods to better understand the capabilities and limitations of the model.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Jan Trost Jorgensen
Summary: Predictive biomarkers play a key role in precision medicine, especially in the development of companion diagnostics for hematological and oncological drugs. The FDA has approved 44 CDx assays by the end of 2020, with diverse analytical platforms requiring rigorous regulatory pathways for approval.
TRANSLATIONAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Dariusz Boron, Nikola Zmarzly, Magdalena Wierzbik-Stronska, Joanna Rosinczuk, Pawel Mieszczanski, Beniamin Oskar Grabarek
Summary: This article provides a detailed overview of the application of multiomics approaches in endometrial cancer research, highlighting their potential in selecting molecular markers and targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Aurelie Bardet, Alderic M. Fraslin, Jamila Marghadi, Isabelle Borget, Matthieu Faron, Charles Honore, Suzette Delaloge, Laurence Albiges, David Planchard, Michel Ducreux, Julien Hadoux, Emeline Colomba, Caroline Robert, Samia Bouhir, Christophe Massard, Jean-Baptiste Micol, Lucile Ter-Minassian, Stefan Michiels, Anne Auperin, Fabrice Barlesi, Julia Bonastre
Summary: This study simulated the impact of changes in the management of cancer patients during the COVID-19 pandemic on hospital resource utilization and patient mortality, finding that pandemic-related diagnostic and treatment delays could increase the risk of cancer patient mortality.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Sylvie Rodrigues-Ferreira, Clara Nahmias
Summary: Breast cancer is a common malignancy among women worldwide, and different treatment options have significantly improved patient outcomes. However, further research on predictive biomarkers is needed to combat treatment resistance and identify the most suitable patients for personalized treatment, aiming to avoid unnecessary overtreatment.
Review
Oncology
Maarten Slebe, Johanna E. E. Pouw, Sayed M. S. Hashemi, C. Willemien Menke-van der Houven van Oordt, Maqsood M. Yaqub, Idris Bahce
Summary: Immune oncology therapy has become an important option for NSCLC patients, but not all patients benefit from it. ImmunoPET has the potential to provide predictive biomarkers and insights into the tumor microenvironment, leading to improved IO and drug development strategies.
